Identification of Lipid Species Signatures in FOLFOXIRI-Resistant Colorectal Cancer Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26031169 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von George M Ramzy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Lipid Metabolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional funding.
Abstract (Originalsprache)
Chronic drug treatment can alter the lipidome of cancer cells, potentially leading to significant biological changes, such as drug resistance or increased tumor aggressiveness. This study examines the lipidome profiles of four human colorectal cancer (CRC) cell lines, comparing treatment-naïve cells with the same cells after chronic exposure to a clinically used combination therapy (FOLFOXIRI: folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan). Lipidomic profiling was obtained with untargeted liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS). For data deconvolution and to interpret the multifactorial dataset generated, Analysis of Variance Multiblock Orthogonal Partial Least Squares (AMOPLS) was used. Our results indicate specific shifts in triglycerides (TGs), sphingolipids, and phospholipids in CRC cells resistant to FOLFOXIRI. The overall shift in TGs, phosphatidylcholine, and cholesteryl ester species was notably linked to FOLFOXIRI resistance (-R) in SW620 cells, whereas an increased abundance of phospholipids, mainly hexosylceramide and sphingomyelin, was present in the signatures of HCT116-R, LS174T-R, and DLD1-R cells. These altered lipid species may serve as potential prognostic markers in CRC following chemotherapy. Furthermore, lipid-targeting therapies aimed at reprogramming the lipid profiles of drug-resistant cells could play a crucial role in restoring drug sensitivity and improving patient survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland.
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.
- Translational Research Center in Oncohaematology, 1211 Geneva, Switzerland.
- Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.
- Biomedical and Metabolomics Analysis Group, School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland.
- Swiss Centre for Applied Human Toxicology (SCAHT), 4055 Basel, Switzerland.
ORCID-Profile: Isabel Meister, Serge Rudaz, Julien Boccard, Patrycja Nowak-Sliwinska
Förderung
- Institutional funding
Zitieren
APA
Ramzy, G. M., Meister, I., Rudaz, S., Boccard, J., & Nowak-Sliwinska, P. (2025). Identification of Lipid Species Signatures in FOLFOXIRI-Resistant Colorectal Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031169
Vancouver
Ramzy GM, Meister I, Rudaz S, Boccard J, Nowak-Sliwinska P. Identification of Lipid Species Signatures in FOLFOXIRI-Resistant Colorectal Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031169
BibTeX
@article{Ramzy2025,
author = {Ramzy, George M and Meister, Isabel and Rudaz, Serge and Boccard, Julien and Nowak-Sliwinska, Patrycja},
title = {Identification of Lipid Species Signatures in FOLFOXIRI-Resistant Colorectal Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26031169}
}
EUVIMED